NACDS strongly supports a Senate letter sent to Health and Human Services (HHS) Secretary Tom Price and Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma on the use of direct and indirect remuneration (DIR) fees.
NACDS outlined concerns about the border adjustment tax (BAT) to the Senate Finance Committee before its hearing this week, "Comprehensive Tax Reform: Prospects and Challenges."
NACDS President and CEO Steven C. Anderson, IOM, CAE, reflects on the policy and political landscapes created by the 2016 elections--and NACDS' forward-thinking approach to them.
NACDS-backed bipartisan provider status legislation—H.R. 592—got a boost from the Americans for Tax Reform (ATR) recently in a letter to Rep. Brett Guthrie (R-KY) stating that the bill could streamline the healthcare system, improve access to care for patients and result in billions of dollars in savings.
Get the latest insights on the industry, healthcare, personal care, front end—and more—delivered straight to your inbox daily when you subscribe to the indispensable NACDS E-ssential newsletter.
A survey conducted among TRICARE beneficiaries by Morning Consult and commissioned by NACDS shows support for the TRICARE Acquisition Cost Parity Pilot Program for Retail Pharmacy.
NACDS welcomed members of the NACDS Board of Directors for a two-day Washington fly-in this week as an increasingly intense debate on healthcare continues to reverberate on the Hill and across the country.
New study results from the Centers for Disease Control and Prevention (CDC) show that mosquitoes that can spread Zika, dengue and chikungunya viruses are in more counties in the southern United States than was previously known.
At the inaugural President's Commission on Combating Drug Addiction and the Opioid Epidemic, healthcare and community advocates provided testimony improving access to treatment and support for community prevention programs. NACDS is monitoring the Commission's progress in addressing these important issues.
The Supreme Court ruled unanimously this week in a decision on biosimilar medications, a ruling that could save patients and the healthcare system billions of dollars.
